Law, medicines and the doctor: a critical look at drug regulation

References

• Sadusk, J. F., (1973). The effect of drug regulation on the development of new drugs. Pharm. Ind., 35, 541–544.1. Sadusk, J. F., (1973). The effect of drug regulation on the development of new drugs. Pharm. Ind., 35, 541–544.
   Google Scholar
• Russell, Taylor W.J., (1973). The Federal Food and Drug Administration in the United States: born and bred in crises. Int. J. clin. Pharmacol., 7, 156–162.2. Russell, Taylor W.J., (1973). The Federal Food and Drug Administration in the United States: born and bred in crises. Int. J. clin. Pharmacol., 7, 156–162.
   PubMedGoogle Scholar
• Anon(1973). Intricacies of new drug registration requirements bring serious problems for the industry; report on a meeting of the International Pharmaceutical Federation. Pharm. J., 35, 311–312.3. Anon, (1973). Intricacies of new drug registration requirements bring serious problems for the industry; report on a meeting of the International Pharmaceutical Federation. Pharm. J., 35, 311–312.
   Google Scholar
• Dunlop, D., and Inch, R. S., (1972). Variations in pharmaceutical and medical practice in Europe. Brit. med. J., 3, 749–752.4. Dunlop, D., and Inch, R. S., (1972). Variations in pharmaceutical and medical practice in Europe. Brit. med. J., 3, 749–752.
   PubMed Web of Science ®Google Scholar
• Cramer, H. J., (1973). Die Arzneipolizei. Pharm. Ind., 35, 237–238.5. Cramer, H. J., (1973). Die Arzneipolizei. Pharm. Ind., 35, 237–238.
   Google Scholar
• Tischler, M., (1973). Drug discovery – background and foreground. Clin. Pharm. Ther., 14, 479–786.6. Tischler, M., (1973). Drug discovery – background and foreground. Clin. Pharm. Ther., 14, 479–786.
   PubMed Web of Science ®Google Scholar
• Editorial(1973). In Search of Novelty. Lancet, 1, 1045–1046.7. Editorial, (1973). In Search of Novelty. Lancet, 1, 1045–1046.
   PubMed Web of Science ®Google Scholar
• Lasagna, L., (1972). Research regulation and development of new pharmaceuticals; past, present and future. Amer. J. med. Sci., 263, 8–11, 66–78.8. Lasagna, L., (1972). Research regulation and development of new pharmaceuticals; past, present and future. Amer. J. med. Sci., 263, 8–11, 66–78.
   Web of Science ®Google Scholar
• Kaldor, A., (1973). Patterns and problems of drug introduction and control. Int. J. clin. Pharmacol., 7, 163–167.9. Kaldor, A., (1973). Patterns and problems of drug introduction and control. Int. J. clin. Pharmacol., 7, 163–167.
   PubMedGoogle Scholar
• Gross, F., (1973). Future drug research – drugs of the future. Clin. Pharm. Ther., 14, 1–11.10. Gross, F., (1973). Future drug research – drugs of the future. Clin. Pharm. Ther., 14, 1–11.
   PubMed Web of Science ®Google Scholar
• Noel, P. R. B., (1973). Present attitudes of governmental drug regulatory agencies. Int. J. clin. Pharmacol., 7, 168–177.11. Noel, P. R. B., (1973). Present attitudes of governmental drug regulatory agencies. Int. J. clin. Pharmacol., 7, 168–177.
   PubMedGoogle Scholar
• World Health Organization, Regional Office for Europe, (1973). Clinical pharmacological evaluation in drug control; report on a symposium. Heidelberg, 27–30 November, 1972. W.H.O., Copenhagen, EUR0.7406.12. World Health Organization, Regional Office for Europe, (1973). Clinical pharmacological evaluation in drug control; report on a symposium. Heidelberg, 27-30 November, 1972. W.H.O., Copenhagen, EUR0.7406.
   Google Scholar
• World Health Organization, Regional Office for Europe, (In press). Clinical pharmacological evaluation in drug control: report on a symposium. Heidelberg, 24–27 September, 1973.13. World Health Organization, Regional Office for Europe, (In press). Clinical pharmacological evaluation in drug control: report on a symposium. Heidelberg, 24–27 September, 1973.
   Google Scholar
• Blake, J. B., (Editor), (1970). “Safeguarding the Public”. The John Hopkins Press, Baltimore and London.14. Blake, J. B., (Editor), (1970). “Safeguarding the Public”. The John Hopkins Press, Baltimore and London.
   Google Scholar
• Anon(1937). Sen. Doc. 124, 75th Congress, 2nd session; (report on the Elixir Sulfanilamide case).15. Anon, (1937). Sen. Doc. 124,75th Congress, 2nd session; (report on the Elixir Sulfanilamide case).
   Google Scholar
• Dukes, M. N. G., (1973). Geneesmiddelenregistratie; de stap naar Benelux. Ned. Tijdschr. Geneesk., 117, 1126–1128.16. Dukes, M. N. G., (1973). Geneesmiddelenregistratie; de stap naar Benelux. Ned. Tijdschr. Geneesk., 117, 1126–1128.
   PubMedGoogle Scholar
• Organisation for Economic Co-operation and Development(1969). “Gaps in Technology: Pharmaceuticals”. OECD Publications, Paris.17. Organisation for Economic Co-operation and Development, (1969). “Gaps in Technology: Pharmaceuticals.” OECD Publications, Paris.
   Google Scholar
• Liljestrand, A., (1973). The comparative efficacy of drugs. (see ref. no. 12).18. Liljestrand, A., (1973). The comparative efficacy of drugs. (see ref. no. 12).
   Google Scholar
• De Maar, E., (1973). Monitoring of marketed drugs: adverse effects. (see ref. no. 12).19. De Maar, E., (1973). Monitoring of marketed drugs: adverse effects. (see ref. no. 12).
   Google Scholar
• World Health Organisation, (1972). “International drug monitoring: the role of national centres.” W.H.O. Tech. Rep. Ser., 1972, No. 498.20. World Health Organisation, (1972). “International drug monitoring: the role of national centres.” W.H.O. Tech. Rep. Ser., 1972, No. 498.
   Google Scholar
• Dollery, C. T., (1968). Drug combinations. Presenters' Journal, 8, 7–11.21. Dollery, C. T., (1968). Drug combinations. Presenters' Journal, 8, 7–11.
   Google Scholar
• Council on Drugs(1970). Fixed-dose combinations of drugs. J. Amer. med. Ass., 213, 1172–1175.22. Council on Drugs, (1970). Fixed-dose combinations of drugs. J. Amer. med. Ass., 213, 1172–1175.
   Web of Science ®Google Scholar
• Cromie, B. W., (1973). Drug combinations. Curr. med. Res. Opin., 1, 78–86.23. Cromie, B. W., (1973). Drug combinations. Curr. med. Res. Opin., 1, 78–86.
   Google Scholar
• Wardell, W. M., (1973). Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison. Clin. Pharm. Ther., 14, 773–790.24. Wardell, W. M., (1973). Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison. Clin. Pharm. Ther., 14, 773–790.
   PubMed Web of Science ®Google Scholar
• Dukes, M. N. G., (1973). Personal view. Brit. med. J., 3, 496.25. Dukes, M. N. G., (1973). Personal view. Brit. med. J., 3, 496.
   Google Scholar
• Modell, W., (1973). Failed and flawed drugs: a frozen resource. Clin. Pharm. Ther., 14, 771–772.26. Modell, W., (1973). Failed and flawed drugs: a frozen resource. Clin. Pharm. Ther., 14, 771–772.
   PubMed Web of Science ®Google Scholar
• W.H.O.. World Health Assembly, Resolution WHA22.50.27. W.H.O. : World Health Assembly, Resolution WHA22.50.
   Google Scholar
• Questions and Answers, (1970). Non-approved uses of FDA-approved drugs. J. Amer. nied. Ats., 211, 1705.Questions and Answers, (1970). Non-approved uses of FDA-approved drugs. J. Amer. nied. Ats., 211, 1705.
   Web of Science ®Google Scholar